Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer
February 04, 2019 at 07:00 am EST
Share
Kyn Therapeutics, announced that it is expanding its management team with the appointment of Douglas Carlson as its chief financial officer. Mr. Carlson’s most recent role was vice president, commercial operations, corporate strategy & business development at Collegium Pharmaceutical, a specialty pharmaceutical company focused on pain management. Doug brings nearly two decades of multi-disciplinary experience in the strategic financial management of biotech and healthcare companies. He joins Kyn at a new stage of its growth with the initiation of EP4 antagonist clinical program and the signing of global strategic collaboration with Celgene on two other immuno-oncology programs. Mr. Carlson joined Collegium Pharmaceutical in 2013 and helped oversee the company’s development from a privately-held, clinical-development stage company to a publicly-traded commercial business. At Collegium, Mr. Carlson led corporate strategy, commercial and business development initiatives, including all aspects of strategic decision support and commercial operations.
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.